PRO MEDICUS LIMITED — Annual Report 2014

Aug 21, 2014

Appendix 4E Preliminary Final Report

Rule 4.2A

Appendix 4E Preliminary Final Report

1. Company details

Name of entity

. Company details ame of entity	. Company details ame of entity
Pro Medicus Limited
ABN or equivalent company reference Financial year ended (‘current period’) 25 006 194 752 30 June 2014 . Results for announcement to the market
					30 June 2013
ASX Listing Rules **Ref **				2014 A$’000		2013 A$’000		% change
2.1	Revenue from continuing operations			14,447		11,374		27.1%
2.2 2.3	Underlying profit (net profit after tax minus one off contributions) Significant one off items (Sale of Amira/Impairment/Currency gains/(losses)) Profit/(Loss) from ordinary activities after tax attributable to members			1,580 (70) 1,509		(646) 5,777 5,131		344.6% (101.2)% (70.6%)
	Net Profit/(Loss) for the period attributable to members			1,509 Down 70.6%
	% change up/(down) of Net Profit/(Loss) for the period attributable to members from the previous corresponding period.
2.4	Dividends (distributions)			Amount per security			Fully Franked amount per security
	Franked dividend amount per security Final Dividend Interim dividend			1.0 cents 1.0 cents			1.0 cents 1.0 cents
2.5	Record date for Final dividends			12 September 2014
	Payment date for Final dividends			3 October 2014

Appendix 4E Page 1

Appendix 4E Preliminary Final Report

	2.6	Australia The Group employs 26 people in Australia who undertake research and development of Pro Medicus products (RIS) as well as sales and service/support functions. The Group’s Australian revenue was 12.2% above last year’ as a result of new sales of both the Visage PACS and Visage RIS products with many sales being for the combined product offering. A growing percentage of these sales being based on the company’s transaction revenue model. Promedicus.net, the company’s e-health offering, continued to hold its strong market position despite increasing competition. North America The Group employs 11 people in North America to fulfil the sales marketing and professional services roles. Revenue from North America increased by 85.1% compared to the previous year. This was largely attributable to new sales and an increase in transaction based revenue from sales of Visage technology as more contracts came on stream. Europe The Group employs 32 employees in its Berlin office who undertake research and development of Visage Imaging products worldwide as well as sales, marketing and service/support functions for the group's European operations. Revenue from our European operations was in line with the previous year increasing by 0.14% Financials Reported profit after tax for the period was $1.51m a decrease of $3.62m (70.6%) from the previous year. Full year revenue of the Group from continuing operations, increased from $11.37m to $14.45m, an increase of 27.1%. The result from the underlying operations for the year was a profit of $1.58m compared to an underlying loss of $0.65m from the previous year. The underlying profit is made up of reported profit after-tax of $1.51m and adding back the after-tax net currency loss of $0.07m. Last year’s underlying loss was made up of reported profit after-tax of $5.13m, less the after-tax profit of $8.61m from the sale of the Amira business and after-tax net currency gain of $0.39m, and adding back the after-tax impairment expense of $3.22m. The key driver of the underlying profit increase was the significant improvement in the performance of the North American operations supplemented by the increase in Australian sales. Shareholder Returns The directors are confident that the holdings of reserve cash is sufficient to underpin the development and expansion needs of the company as the business looks to increase its penetration of existing markets.
	3.	Statement of Comprehensive Income Please refer to the Statement of Comprehensive Income in the attached Financial Statements.
	4.	Statement of Financial Position Pleasereferto the Statement of Financial Position inthe attachedFinancialStatements.
	5.	Statement of cash flows Pleasereferto the Statement ofcash flowsinthe attachedFinancialStatements.

Appendix 4E Page 2

Appendix 4E Preliminary Final Report

		Appendix 4E Preliminary Final Report
	6.	Details of Dividends 2014 $’000 2013 $’000 Final Dividend A Final Dividend of 1.0 cents (2013: 1.0 cents) per share fully franked will be paid on 3 October 2014. 1,002 1,002 Current Year Interim An interim dividend of 1.0 cents (2013: 1.0 cents) per share fully franked was paid on 21 March 2014. 1,002 1.002 No foreign sourced dividend or distribution is included in either the interim or final dividends.
	7.	Dividend or Distribution reinvestment plans There are no dividend or distribution reinvestment plans in operation.
	8.	Statement of Retained Earnings Please refer to Statement of Changes in Equity in the attached Financial Statements.
	9.	Net Tangible Assets per security 2014 2013 Net Tangible Assets per security $0.13 $0.15
	10.	Details of entities over which control has been gained or lost during the period There are no entities over which control has been gained or lost during the period
	11.	Associates and joint venture entities There are no associates or joint venture entities
	12.	Other significant information needed by an investor to make an informed assessment of the entity’s financial performance and financial position. Please refer to section 2.6
	13.	Foreign Entity accounting standards Australian Accounting Standards &International Financial Reporting Standards

Appendix 4E Page 3

Appendix 4E Preliminary Final Report

14. Commentary on results for the period. The earnings per security and the nature of any dilution aspects . Please refer to Note 9 of the attached Financial Statements.

Returns to shareholders including distributions and buy backs. Please refer to Note 10 of the attached Financial Statements.

Significant features of operating performance . Please refer to section 2.6.

The results of segments that are significant to an understanding of the business. Please refer to Note 5 of the attached Financial Statements.

Discussion of trends in performance. Please refer to section 2.6.

15. Audit Statement

This report is based on accounts to which one of the following applies. (Tick one)

 The +accounts have been  The[+] accounts have been subject to audited. review. [The ] +accounts are in the [The ][+][accounts have ] [not][yet][been ] process of being audited. audited or reviewed.

Sign here:

Date: 22 August 2014

==> picture [209 x 68] intentionally omitted <==

Print name: Sam Hupert Chief Executive Officer

Appendix 4E Page 4